SWI Initiates Coverage on “NeoStem”

January 20, 2015

Overview

NeoStem: NASDAQ:NBS

  • Integrated biotechnology Company with as strong pipeline based on multiple platform technologies that include Phase 2 and 3 assets and a revenue generating contract development and manufacturing business
  • Five (5) issued patents, seventeen (17) matter and method patterns and fourty-four (44) pending patents
  • Exclusive rights to twenty-three (23) issued and nine (9) pending patents
    in-licensed from the University of Louisville to the world-wide patent rights for the isolation, purification and therapeutic use of very small embryo-like (VSEL) stem cells
  • Headquarters in New York
  • GMP compliant facilities in Allendale-NJ, Mountain View-CA and 
    Irvine-CA
  • 168 employees as of September 30, 2014
  • Executed six sector specific acquisitions
  • NASDAQ CM: NBS
  • Market Cap $144 Mill
  • $32.8 Mill in cash and marketable securities as of September 30, 2014

https://stockwatchindex.com/neostem/

Search

RECENT PRESS RELEASES